Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

EHA 2020

11 - 14 Jun 2020
Messe Frankfurt, Frankfurt, Germany
Global rates of influenza and pneumococcal vaccination in multiple myeloma patie...
Dr Michael Thompson - Aurora Health Care, Milwaukee, USA
Global rates of influenza and pneumococcal vaccination in multiple myeloma patients in INSIGHT MM ( Dr Michael Thompson - Aurora Health Care, Milwaukee, USA )
14 Sep 2020
Total body radiation vs chemotherapy-based conditioning in children and adolesce...
Prof Christina Peters - Children's Cancer Research Institute, Vienna, Austria
Total body radiation vs chemotherapy-based conditioning in children and adolescents with ALL ( Prof Christina Peters - Children's Cancer Research Institute, Vienna, Austria )
9 Sep 2020
Evaluating the impact of daratumumab for the treatment of multiple myeloma accor...
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA
Evaluating the impact of daratumumab for the treatment of multiple myeloma according to cytogenetic risk ( Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA )
10 Jul 2020
MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD res...
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA
MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD response-adapted consolidation in NDMM ( Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA )
9 Jul 2020
UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for pati...
Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK
UKALL2011: Treatment with a tyrosine kinase inhibitor improves outcomes for patients with acute lymphoblastic leukaemia and an ABL-class fusion ( Prof Anthony Moorman - Newcastle University, Newcastle upon Tyne, UK )
9 Jul 2020
Long-term disease control in multiple myeloma by in-class transitioning: A commu...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
Long-term disease control in multiple myeloma by in-class transitioning: A community-based study ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )
3 Jul 2020
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma ( Dr Elias Jabbour -  MD Anderson Cancer Center, Houston, USA )
3 Jul 2020
Gut microbiome disturbance by antibiotic treatment early in life is sufficient t...
Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Sala...
Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice ( Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Salamanca, Spain )
30 Jun 2020
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patient...
Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )
26 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
26 Jun 2020
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )
26 Jun 2020
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients w...
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )
26 Jun 2020
New CAR T therapy for relapsed and refractory ALL
Dr Claire Roddie - University College London, London, UK
New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )
25 Jun 2020
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma
Prof Philippe Moreau - University of Nantes, Nantes, France
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
25 Jun 2020
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythe...
Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )
25 Jun 2020
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexame...
Prof Efstathios Kastritis - University of Athens, Athens, Greece
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis ( Prof Efstathios Kastritis - University of Athens, Athens, Greece )
25 Jun 2020
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blina...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymp...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020
Maintenance treatment in multiple myeloma: A new era
Prof Sagar Lonial and Prof Wee-Joo Chng
Maintenance treatment in multiple myeloma: A new era ( Prof Sagar Lonial and Prof Wee-Joo Chng )
18 Jun 2020
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-cla...
Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA
US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )
13 Jun 2020
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neo...
Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )
13 Jun 2020
Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )
13 Jun 2020
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myelo...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020
AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory mu...
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
13 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior l...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
Patient reported outcomes for the CANDOR trial for multiple myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Patient reported outcomes for the CANDOR trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020